BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer
Open Access
- 27 November 2024
- journal article
- research article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 16 (1) , 1-10
Abstract
In high-grade ovarian cancer (HGOC), determination of homologous recombination deficiency (HRD) status is commonly used in routine practice to predict response to platinum-based therapy or poly (ADP-ribose) polymerase inhibitors (PARPi). Here we tested the hypothesis that BRCA loss of function (LOF) due to epigenetic or genetic aberrations is a better predictor for the clinical outcome than HRD. One hundred thirty-one HGOC tissues were tested for BRCA DNA-methylation, BRCA mutations, HRD and BRCA1 mRNA expression, followed by a comprehensive survival analysis. BRCA1-methylation was detected in 11% of the tumors, exclusively in BRCA1-wild-type (wt) HGOCs. BRCA1-methylated tumors (BRCA1-meth) had HRD-scores similar to those of BRCA-mutated (mut) tumors, and higher compared to unmethylated-BRCA-wt tumors (BRCA-wt-unmeth; P < 0.001). Platinum-refractory or -resistant HGOCs at first recurrence were all BRCA-unmeth cancers. Only one of the BRCA-mut cancers had a platinum-resistant recurrence. Thus, 99% of relapses in cancers with epigenetic or genetic BRCA-alterations were platinum-sensitive. Multivariate analysis confirmed BRCA-LOF as an independent predictor of progression-free survival (PFS) and overall survival (OS), whereas HRD-status had no predictive value for PFS and OS. Patients with BRCA-wt-unmeth cancers had the worst outcome compared to patients with cancers harboring epigenetic or genetic BRCA-alterations (PFS: P = 0.007; OS: P = 0.022). Most importantly, the BRCA-wt-unmeth subfraction of HRD-positive HGOCs exhibited the same poor survival as the entire HRD-negative cohort. In HGOC BRCA mutational status together with BRCA1-methylation exhibit the best predictive power for favorable clinical outcome and thus high sensitivity to platinum-based therapy, whereas BRCA-unrelated HRD positivity was not associated with improved platinum sensitivity.Keywords
Funding Information
- Verein zur Krebsforschung in der Frauenheilkunde
This publication has 34 references indexed in Scilit:
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging AgentsCancer Discovery, 2012
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian CancerJAMA, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer, 2005
- Frequency of BRCA1 Dysfunction in Ovarian CancerJNCI: Journal of the National Cancer Institute, 2002
- BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.2000
- Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristicsOncogene, 1999